Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 18, 2019 08:00 ET | Source: Celsion CORP

Celsion’s New Subsidiary in China to Serve as Beachhead for Commercializing ThermoDox® in China and Southeast Asia

Memorandum of Understanding completed with Chinese government officials in the Yuhang district of Hangzhou, China’s biotech hub, to develop and commercialize innovative cancer therapies starting with...
December 17, 2019 08:00 ET | Source: Celsion CORP

Celsion Receives $2.0 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program

Non-Dilutive Funding Strengthens Balance Sheet; Proceeds Equate to More Than $0.08 Per Share Assures Funding Through Major Company Events; Company Provides Guidance on the Timing of Upcoming...
November 14, 2019 16:05 ET | Source: Celsion CORP

Celsion Corporation Reports Third Quarter 2019 Financial Results and Provides Business Update

Independent Data Monitoring Committee (iDMC) Unanimously Recommends Continuation of Phase III OPTIMA Study at First Pre-Planned Efficacy AnalysisIndependent Data Safety Monitoring Board (DSMB)...
November 14, 2019 08:00 ET | Source: Celsion CORP

Celsion Announces Publication of Research on Fluorescence Imaging of ThermoDox® Uptake in International Journal of Hyperthermia

Independent Analysis Confirms Increasing Heating Time + ThermoDox® Improves Tumor Uptake of Drug, which may be visualized by real-time fluorescence imaging Study Confirms that ThermoDox® Can Deliver...
November 08, 2019 08:30 ET | Source: Celsion CORP

Celsion Corporation to Hold Third Quarter 2019 Financial Results Conference Call on Friday, November 15, 2019

Company to Provide Clinical Development Update on its Phase III OPTIMA Study in Primary Liver Cancer and its Phase I/II OVATION 2 Study in Ovarian Cancer LAWRENCEVILLE, N.J., Nov. 08, 2019 (GLOBE...
November 05, 2019 08:00 ET | Source: Celsion CORP

Celsion Announces DSMB Recommendation to Continue GEN-1 at 100mg/m² Dose to Complete the Phase I Portion of OVATION 2 Study in Ovarian Cancer

GEN-1 Manufacturing Technology Transfer Successfully Produces High-Quality Affordable Investigational Product for Use in Clinical Trials LAWRENCEVILLE, N.J., Nov. 05, 2019 (GLOBE NEWSWIRE) --...
November 04, 2019 08:00 ET | Source: Celsion CORP

Celsion Reports Unanimous Independent Data Monitoring Committee Recommendation to Continue the Phase III OPTIMA Study of ThermoDox® in Primary Liver Cancer

The Data Monitoring Committee Signals that Patient Safety Data and Data Quality Meets Expectations and Company is to Proceed to Next Interim Analysis.The Pooled Progression-Free Survival (PFS) Data is...
October 01, 2019 08:00 ET | Source: Celsion CORP

Celsion Strengthens Its 2019 Balance Sheet with the Approval of Its Application to Sell Net Operating Losses for $2.1 Million in Non-Dilutive Funding

$2 Million in Additional NOL Sales are Available to the Company in 2020 Funding Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program LAWRENCEVILLE, N.J., Oct. 01,...
September 30, 2019 14:30 ET | Source: Celsion CORP

Celsion to Present at the Chardan 3rd Annual Genetic Medicines Conference

LAWRENCEVILLE, N.J., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces that Michael Tardugno, Chairman, President and Chief...
September 23, 2019 08:00 ET | Source: Celsion CORP

Celsion Co-sponsors Hepatocellular Carcinoma Symposium at the International Liver Cancer Association (ILCA) Annual Conference

LAWRENCEVILLE, N.J., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces it co-sponsored a symposium focused on hepatocellular...

keyboard_arrow_left Previous Page